Research Article
The Clinical and Cellular Impact of RBMS2 on the Progression and Prognosis of Kidney Renal Clear Cell Carcinoma
Table 1
ccRCC patients’ characteristics and correlations with RBMS2 expression level.
| Characteristics | Low expression of RBMS2 | High expression of RBMS2 | value |
| n | 270 | 271 | | Gender, n (%) | | | 0.092 | Female | 84 (15.5%) | 103 (19%) | | Male | 186 (34.4%) | 168 (31.1%) | | Age, n (%) | | | 0.035 | ≤60 | 122 (22.6%) | 147 (27.2%) | | >60 | 148 (27.4%) | 124 (22.9%) | | Serum calcium, n (%) | | | 0.002 | Low | 90 (24.5%) | 114 (31.1%) | | Normal and elevated | 98 (26.7%) | 65 (17.7%) | | Histologic grade, n (%) | | | <0.001 | G1 and G2 | 96 (18%) | 154 (28.9%) | | G3 and G4 | 168 (31.5%) | 115 (21.6%) | | Pathologic T stage, n (%) | | | <0.001 | T1 and T2 | 150 (27.7%) | 200 (37%) | | T3 and T4 | 120 (22.2%) | 71 (13.1%) | | Pathologic N stage, n (%) | | | 0.400 | N0 | 125 (48.4%) | 117 (45.3%) | | N1 | 10 (3.9%) | 6 (2.3%) | | Pathologic M stage, n (%) | | | <0.001 | M0 | 201 (39.6%) | 228 (44.9%) | | M1 | 53 (10.4%) | 26 (5.1%) | | Pathologic stage, n (%) | | | <0.001 | Stage I and stage II | 138 (25.7%) | 194 (36.1%) | | Stage III and stage IV | 129 (24%) | 77 (14.3%) | |
|
|